Ten23 Health and Becton Dickinson enter into strategic partnership

(CONNECT) The Basel-based biotechnology company ten23 Health is cooperating with the US medtech firm BD from the state of New Jersey, with the aim of supporting the commercialization of the BD Libertas Wearable Injector as a full-service solution. According to a statement, the collaboration will offer biopharmaceutical companies a “fully integrated, ready-to-use solution for the subcutaneous delivery of large-volume drugs”. At the same time, this should help to reduce risks in relation to complex injectable programs.

The partnership includes the injector with a 5-milliliter or 10-milliliter glass cartridge. This is supported by services provided by ten23 in the areas of process development, aseptic filling, assembly and quality control. Pharmaceutical partners will be able to take advantage of the BD Libertas platform as well as ten23’s development and manufacturing services to bring high-volume, subcutaneous treatments to market and into clinical practice, thereby ensuring flexibility and ease of use for patients.

“Enabling successful patient treatment on behalf of our customers is a key priority for ten23”, comments Hanns-Christian Mahler, Chief Enablement Officer at ten23 health, in the statement. “Based on the already successful collaboration of ten23 with BD for the BD iDFill solution, we are happy to expand our collaboration to also include BD Libertas Wearable Injector platform”, he concludes.

Ten23 recently announced Line 0, a robot-assisted pilot line that will allow pharmaceutical customers to test cartridge compatibility, conduct stability studies and optimize filling and stopper adjustment processes under representative conditions, without the delays or costs associated with production activities in line with GMP (Good Manufacturing Practice) production. ce/nta